Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the indexes in months.
LONDON - April 30, 2025 - PRLog -- Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis, leading provider of CARA Platform for Content and Data management, to digitise and streamline Quality processes.With over 170 years of experience in the pharmaceutical industry, Kwizda Pharma develops proprietary over-the-counter (OTC) drugs and operates as a Contract Manufacturing Organisation (CMO). Kwizda Pharma required a system to upgrade from paper-based and manual processes such as MS Excel trackers for managing quality documentation and training, which led to inefficiencies in compliance tracking, audits, and quality management reviews."Maintaining an up-to-date and compliant quality system was becoming increasingly difficult," states Desiree Womser-Matlschweiger, Head of QA at Kwizda Pharma. "Training management, in particular, posed significant challenges, as tracking employee training and physical signatures was a time-consuming process."Kwizda Pharma selected the CARA Life Sciences Platform for its out-of-the-box (OOTB) configuration, rapid implementation timeline due to minimal additional validation, and cost-effectiveness for smaller companies. The company needed a solution that would allow a seamless transition from paper-based workflows without the burden of lengthy customisations. Additionally, as a CMO, the ability to securely include external collaborators on the platform was an important factor in the selection process."CARA's pre-validated, fully compliant solution was ideal for us, as it reduces the burden internally to handle system validation," Desiree added. "The responsiveness and expertise of the Generis team made for an incredibly smooth selection process; they understood our needs and made the choice simple."Phase one of the implementation focuses on quality document management and read & understood training workflows, this is set to go live by the end of June. The second phase of the implementation, planned for later this year, will expand the system's capabilities to include a full Quality Management System (QMS) and advanced Learning Management System (LMS) features. Kwizda Pharma also intends to integrate its ERP system to further enhance operational efficiency. By choosing CARA, Kwizda Pharma can consolidate different systems and move away from paper-based processes.The company looks forward to improved audit readiness and overall quality oversight with the CARA Life Sciences Platform. "Audits are currently quite challenging with our paper-based processes. With CARA, we anticipate a more efficient and transparent audit process, allowing us to focus on continuous improvement." Added Desiree.By eliminating manual workflows and paper-based processes, Kwizda Pharma expects to see significant efficiency gains across its quality operations. The latest CARA version also includes the 'AI Assistant' which will enable Kwizda Pharma to easily incorporate AI use in the future. The CARA Life Sciences Platform will provide real-time visibility into quality metrics, reduce the administrative burden of compliance management, and ensure seamless collaboration both internally, and with external partners.About GenerisGeneris is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at www.caralifesciences.generiscorp.com .About Kwizda PharmaKwizda Pharma is a division of Kwizda Holding GmbH, a family-run Austrian company with a long-standing reputation in the healthcare sector. With more than 170 years of experience, Kwizda Pharma develops proprietary over-the-counter (OTC) drugs and provides pharmaceutical services ranging from development to supply. The company operates internationally and also functions as a Contract Manufacturing Organisation (CMO), supporting high-quality pharmaceutical production and distribution.
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA).
Pfizer Inc. chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in the US.
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.92 per share was 35.2% above analysts’ consensus estimates.
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
